eIF2 Alpha (EIF2S1) — Eukaryotic Initiation Factor 2 Alpha
<table class="infobox infobox-protein">
<tr><th class="infobox-header" colspan="2">eIF2α (EIF2S1)</th></tr>
<tr><td class="label">Gene</td><td><a href="/genes/eif2s1">EIF2S1</a></td></tr>
<tr><td class="label">UniProt ID</td><td><a href="https://www.uniprot.org/uniprot/P05198">P05198</a></td></tr>
<tr><td class="label">Molecular Weight</td><td>36.1 kDa</td></tr>
<tr><td class="label">Subcellular Localization</td><td>Cytoplasm</td></tr>
<tr><td class="label">Protein Family</td><td>eIF2 alpha subunit family</td></tr>
</table>
Overview
eIF2α (eukaryotic initiation factor 2 alpha, encoded by EIF2S1) is the regulatory subunit of the heterotrimeric eIF2 complex (eIF2α/β/γ). The eIF2 complex is essential for the first step of eukaryotic translation initiation: delivery of the initiator Met-tRNA to the 40S ribosomal subunit in a GTP-dependent manner. Phosphorylation of eIF2α at serine 51 by any of four stress-activated kinases (PERK/EIF2AK3, HRI/EIF2AK1, PKR/EIF2AK2, GCN2/EIF2AK4) inhibits the guanine nucleotide exchange factor eIF2B, globally suppressing cap-dependent translation while paradoxically inducing expression of stress-responsive mRNAs including ATF4. This integrated stress response (ISR) is a critical adaptive mechanism, but chronic ISR activation is emerging as a driver of synaptic failure and neuronal death across multiple neurodegenerative diseases.
Mechanism of Action in Neurodegeneration
...eIF2 Alpha (EIF2S1) — Eukaryotic Initiation Factor 2 Alpha
<table class="infobox infobox-protein">
<tr><th class="infobox-header" colspan="2">eIF2α (EIF2S1)</th></tr>
<tr><td class="label">Gene</td><td><a href="/genes/eif2s1">EIF2S1</a></td></tr>
<tr><td class="label">UniProt ID</td><td><a href="https://www.uniprot.org/uniprot/P05198">P05198</a></td></tr>
<tr><td class="label">Molecular Weight</td><td>36.1 kDa</td></tr>
<tr><td class="label">Subcellular Localization</td><td>Cytoplasm</td></tr>
<tr><td class="label">Protein Family</td><td>eIF2 alpha subunit family</td></tr>
</table>
Overview
eIF2α (eukaryotic initiation factor 2 alpha, encoded by EIF2S1) is the regulatory subunit of the heterotrimeric eIF2 complex (eIF2α/β/γ). The eIF2 complex is essential for the first step of eukaryotic translation initiation: delivery of the initiator Met-tRNA to the 40S ribosomal subunit in a GTP-dependent manner. Phosphorylation of eIF2α at serine 51 by any of four stress-activated kinases (PERK/EIF2AK3, HRI/EIF2AK1, PKR/EIF2AK2, GCN2/EIF2AK4) inhibits the guanine nucleotide exchange factor eIF2B, globally suppressing cap-dependent translation while paradoxically inducing expression of stress-responsive mRNAs including ATF4. This integrated stress response (ISR) is a critical adaptive mechanism, but chronic ISR activation is emerging as a driver of synaptic failure and neuronal death across multiple neurodegenerative diseases.
Mechanism of Action in Neurodegeneration
The ISR is activated by the convergent phosphorylation of eIF2α at Ser51. Each of the four kinases senses a distinct upstream stress: PERK responds to misfolded proteins in the ER, GCN2 to amino acid deprivation, PKR to double-stranded RNA, and HRI to heme deficiency and oxidative stress. In neurodegenerative disease, multiple stresses are simultaneously present, resulting in persistent multi-kinase-driven eIF2α phosphorylation that outlasts acute adaptive needs. This chronic state suppresses synaptic protein synthesis, impairs long-term potentiation, and over time triggers ATF4-mediated expression of pro-death genes.
In prion disease, misfolded prion protein (PrPSc) accumulates in the ER and triggers sustained PERK-mediated eIF2α phosphorylation. Synaptic loss, which precedes neuronal death, was directly linked to translational repression in infected mice. Reducing eIF2α phosphorylation pharmacologically rescued synaptic protein levels, reversed synapse loss, and extended survival in prion-infected mice, establishing ISR as a causal driver rather than an epiphenomenon of neurodegeneration. PMID: 24107777 Restoring translation by the small molecule ISRIB (integrated stress response inhibitor), which activates eIF2B directly and bypasses eIF2α phosphorylation, similarly prevented synaptic failure and extended survival, providing an alternative pharmacological proof-of-concept. PMID: 25741597
In Alzheimer's disease, eIF2α phosphorylation is elevated in post-mortem temporal cortex and hippocampus, particularly in neurons bearing neurofibrillary tangles. The PERK kinase gene EIF2AK3 harbors common variants associated with increased AD and PSP risk in GWAS studies. PERK-mediated phosphorylation of eIF2α has been shown to promote tau hyperphosphorylation by upregulating CDK5 through ATF4-mediated transcription, creating a direct mechanistic link between ER stress and tauopathy. PMID: 36563857 In ALS, mutant SOD1 and TDP-43 aggregates trigger ER stress through PERK and IRE1, and markers of ISR activation correlate with motor neuron vulnerability.
Key Experimental Evidence
Prion disease mouse models: Genetic reduction of PERK activity in prion-infected mice normalized eIF2α phosphorylation, restored synaptic protein synthesis, and extended lifespan by ~30%, establishing PERK-eIF2α as a causal neurodegeneration pathway. PMID: 24107777 Pancreatic toxicity from systemic PERK inhibition prompted development of eIF2B activators as an alternative approach.
ISRIB: The small molecule ISRIB binds eIF2B and renders it insensitive to inhibition by phospho-eIF2α, thereby restoring global translation without blocking the kinase itself. ISRIB treatment of prion-infected mice from symptom onset significantly delayed neurodegeneration, validating eIF2B as the therapeutic effector node. PMID: 25741597 Subsequent work showed ISRIB enhances memory consolidation in rodents, suggesting a broad role for eIF2α phosphorylation in synaptic plasticity.
EIF2AK3/PERK and tau: A 2023 study showed that genetic variants in EIF2AK3 that increase PERK activity directly enhance tau protein aggregation, with PERK-specific inhibition reversing tau accumulation, linking ISR to tauopathy at the molecular level. PMID: 36563857
Hereditary spastic ataxia: A 2024 study demonstrated that sustained OMA1-mediated mitochondrial stress activates the ISR in a spastic ataxia mouse model, and that genetic reduction of ISR signaling was neuroprotective, extending the ISR-neurodegeneration axis to mitochondrial diseases. PMID: 37804316
iPSC models: Patient-derived iPSC neurons from AD and FTD donors show elevated phospho-eIF2α, and ISRIB or eIF2α dephosphorylation rescues translational output and synapse density, directly validating ISR inhibition as a strategy in human neurons.
Current Therapeutic Targeting Strategies
| Strategy | Agent | Mechanism | Stage |
|----------|-------|-----------|-------|
| PERK inhibition | GSK2606414, LY3405105 | Block eIF2α phosphorylation upstream | Preclinical; Phase I |
| eIF2B activation | ISRIB | Bypass eIF2α phosphorylation | Preclinical |
| eIF2B activation (CNS) | DNL343 | CNS-penetrant eIF2B activator | Phase II ALS |
| Selective kinase inhibition | PKR inhibitor C16 | Block pathologic kinase branch | Preclinical |
| eIF2α dephosphorylation | Salubrinal, guanabenz | Prolong eIF2α dephosphorylation | Preclinical |
DNL343 (Denali Therapeutics), a CNS-penetrant eIF2B activator, entered a Phase II clinical trial in ALS in 2022, representing the first ISR-targeting agent to reach clinical development for neurodegeneration.
Open Questions and Knowledge Gaps
- Which ISR kinase dominates in each disease context, and does the answer vary by cell type or disease stage?
- Whether chronic eIF2α phosphorylation drives primarily synaptic dysfunction, neuronal apoptosis, or both
- How to achieve therapeutic ISR modulation while preserving the acute adaptive function of the response
- The role of ATF4 downstream targets in mediating neurodegeneration versus neuroprotection
- Biomarkers in CSF or plasma that reflect ISR activity in living patients
Related Pages
- [PERK/EIF2AK3](/genes/eif2ak3)
- [Unfolded Protein Response](/mechanisms/unfolded-protein-response)
- [Integrated Stress Response](/mechanisms/integrated-stress-response)
References
- PMID: 24107777 Moreno JA et al. Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. Sci Transl Med 2013;5(206):206ra138.
- PMID: 25741597 Halliday M et al. Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity. Cell Death Dis 2015;6:e1672.
- PMID: 36563857 Radford H et al. Neurodegeneration risk factor EIF2AK3 (PERK) influences tau protein aggregation. J Biol Chem 2023;299(2):102793.
- PMID: 37804316 Caballero-Bermejo M et al. Sustained OMA1-mediated integrated stress response is beneficial for spastic ataxia. Brain 2024;147(3):848-860.
- PMID: 19078956 Costa-Mattioli M et al. eIF2α phosphorylation bidirectionally regulates the switch from short- to long-lasting synaptic plasticity and memory. Nature 2007;452(7185):272-277.
- PMID: 23114593 Moreno JA et al. Sustained translational repression by eIF2α-P mediates prion neurodegeneration. Nature 2012;485(7399):507-511.